Search

Displaying results 2111 - 2120 of 5392 in total
  1. Drug

    Sipavibart

    go.drugbank.com/drugs/DB21908
    ApprovedInvestigational

    Sipavibart is a recombinant human IgG1 monoclonal antibody that is long-acting. It works by binding to the SARS-CoV-2 spike protein receptor binding domain (RBD), neutralize the virus and preventing its entry into the host cell. Sipaviba...

  2. Drug

    Propoxycaine

    go.drugbank.com/drugs/DB09342
    Approved

    Propoxycaine is a local anesthetic of the ester type that has a rapid onset of action and a longer duration of action than procaine hydrochloride . This drug was removed from the US market in 1996. Although no longer available in the Uni...

  3. Drug

    GTB-3550

    go.drugbank.com/drugs/DB18494
    Investigational

    single-chain, tri-specific scFv recombinant fusion protein conjugate composed of the variable regions of the heavy and light chains of anti-CD16 and anti-CD33 antibodies and a modified form of Interleukin 15 (IL

    Synonyms: single chain recombinant trispecific killer engager consistent of anti-CD16 scFV spliced to anti-CD33 scFV with a modified IL-15 linker
  4. Drug

    COVID19 s-vax loaded autologous dendritic cell vaccine

    go.drugbank.com/drugs/DB15814
    Experimental

    This vaccine was developed and tested by Beijing TIL Therapeutics. … DC-based vaccines are currently used in cancer therapeutics, and are being tested for COVID-19.

  5. Drug

    Itepekimab

    go.drugbank.com/drugs/DB16206
    Investigational

    Itepekimab is under investigation in clinical trial NCT03546907 (Proof-of-concept Study to Assess the Efficacy, Safety and Tolerability of SAR440340 (Anti-il-33 Mab) in Patients With Moderate-to-severe

  6. Drug

    Etranacogene dezaparvovec

    go.drugbank.com/drugs/DB16791
    ApprovedInvestigational

    [L44161] Men are most likely to experience symptomatic illness due to the X-linked provenance of the disorder. … L44161] Treatment of hemophilia B primarily involves the routine replacement of factor IX using recombinant or donor-derived factor IX products that, while effective, may be burdensome for the patient due

  7. Drug

    Stem bromelain

    go.drugbank.com/drugs/DB12249
    Approved

    The primary therapeutic use for which stem bromelain is currently and formally indicated is as a burn wound eschar debridement agent that has been approved by the EMA since 2012 and marketed under the brand name Nexobrid [FDA Label]. Bro...

  8. Target

    Carbonic anhydrase

    go.drugbank.com/bio_entities/BE0009965
    TargetEnzymeHumans

    Catalyzes the reversible hydration of carbon dioxide (PubMed:10550681, PubMed:16506782, PubMed:16686544, PubMed:16807956, PubMed:17127057, PubMed:17314045, PubMed:17407288, PubMed:19186056, PubMed:19206230, PubMed:4994926). Can hydrate c...

    Synonyms: CA-VI, CA-VII
  9. Drug

    Erenumab

    go.drugbank.com/drugs/DB14039
    ApprovedInvestigational

    Erenumab (AMG-334) (INN; trade name Aimovig) is a human monoclonal antibody designed specifically to bind and antagonize the calcitonin gene-related peptide receptor (CGRPR) as a means to prevent migraines. Aimovig, as released and marke...

  10. Drug

    Pegaspargase

    go.drugbank.com/drugs/DB00059
    ApprovedInvestigational

    Pegaspargase is a conjugate of monomethoxypolyethylene glycol (mPEG) and L-asparaginase (L-asparagine amidohydrolase), an asparagine-specific enzyme that converts L-asparagine into aspartic acid and ammonia. Asparagine is an amino acid t...

    Products: ONCASPAR® 750 U/ML POLVO PARA SOLUCIÓN INYECTABLE, ONCASPAR POWDER FOR SOLUTION FOR INJECTION/INFUSION 750 U/ML